Huntington Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Huntington
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Huntington News
Engineered protein markers read living brain gene activity in monkeys via blood
Gene therapy has been successfully used to treat a number of diseases, including immune deficiencies, hereditary blindness, hemophilia and, recently, Huntington's disease, a fatal neurological ...
A Blood Test That Can Track Gene Activity in the Brain
Researchers demonstrated that released markers of activity (RMAs), engineered proteins that cross the blood-brain barrier and persist in blood, function in monkeys as in mice. The platform enables ...
Zanetti Explores Tech History: Past & Present
Caltech is filled with inventors, people who create everything from scientific instruments to medical devices, from powerful new algorithms to ...
Uniqure falls as FDA demands new trial for Huntington’s gene therapy
The latest firm caught between the FDA’s shifting demands for “gold standard” science and regulatory flexibility for rare disease therapies, Uniqure NV saw its shares plummet after disclosing that U.S ...